SDHD and leprosy: PGL-1 antibodies against M leprae can be measured using enzyme-linked immunosorbent and immunoassays.[77–80] The levels of PGL-1 antigens in clinical specimens are a valuable parameter for predicting bacterial load and can be used to monitor the effectiveness of chemotherapy against leprosy.[89–91] These antigens are present on the cell walls of M leprae and can be detected early in patients, thus providing timely treatment.[91] PGL-1 antibody detection is commonly used to classify patients with leprosy into MB and PB groups.